ArticleOncotarget2018
Differential prognostic impact of interleukin-34 mRNA expression and infiltrating immune cell composition in intrinsic breast cancer subtypes.
Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 36 citations in OpenAlex.
- Proteoglycans in Breast Cancer: Friends and Foes.Biomolecules · 2025Review
- [Expression of interleukin-34 in tongue squamous cell carcinoma and its clinical implications].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2023Article
- Targeted Therapy of Interleukin-34 as a Promising Approach to Overcome Cancer Therapy Resistance.Cancers · 2023Review
- Interleukin-34 and immune checkpoint inhibitors: Unified weapons against cancer.Frontiers in oncology · 2023Review
- Advances with metal oxide-based nanoparticles as MDR metastatic breast cancer therapeutics and diagnostics.RSC advances · 2022Review
- Differential Expression and Prognostic Correlation of Immune Related Factors Between Right and Left Side Colorectal Cancer.Frontiers in oncology · 2022Article
- A robust experimental and computational analysis framework at multiple resolutions, modalities and coverages.Frontiers in immunology · 2022Article
- Interleukin-34 promotes tumorigenic signals for colon cancer cells.Cell death discovery · 2021Review
- Interleukin-34-CSF1R Signaling Axis Promotes Epithelial Cell Transformation and Breast Tumorigenesis.International journal of molecular sciences · 2021Article
- The twin cytokines interleukin-34 and CSF-1: masterful conductors of macrophage homeostasis.Theranostics · 2021Review
- Loss of IL-34 Expression Indicates Poor Prognosis in Patients With Lung Adenocarcinoma.Frontiers in oncology · 2021Article
- Gene Targets Network Analysis for the Revealing and Guidance of Molecular Driving Mechanism of Lung Cancer.Frontiers in genetics · 2021Article
- Macrophages produce and functionally respond to interleukin-34 in colon cancer.Cell death discovery · 2020Article
- Article
- Involvement of the M-CSF/IL-34/CSF-1R pathway in malignant pleural mesothelioma.Journal for immunotherapy of cancer · 2020Article
- Emerging roles of IL-34 in health and disease.The Journal of experimental medicine · 2020Review
- Role of Interleukin-34 in Cancer.Cancers · 2020Review
- Interleukin-34 mediated by hepatitis B virus X protein via CCAAT/enhancer-binding protein α contributes to the proliferation and migration of hepatoma cells.Cell proliferation · 2019Article
- Low infiltration of tumor-associated macrophages in high c-Myb-expressing breast tumors.Scientific reports · 2019Article
- Efficacy of an RNA-based multigene assay with core needle biopsy samples for risk evaluation in hormone-positive early breast cancer.BMC cancer · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interleukin-34 (IL-34) is a ligand for the CSF-1R and has also two additional receptors, PTPRZ1 and syndecan-1. IL-34 plays a role in innate immunity, inflammation, and cancer. However, the role of IL-34 in breast cancer is still ill-defined. We analyzed IL-34 mRNA expression in breast cancer cell lines and breast cancer patients and applied established computational approaches (CIBERSORT, ESTIMATE, TIMER, TCIA), to analyze gene expression data from The Cancer Genome Atlas (TCGA). Expression of IL-34 was associated with a favorable prognosis in luminal and HER2 but not basal breast cancer patients. Gene expression of CSF-1 and CSF-1R was strongly associated with myeloid cell infiltration, while we found no or only weak correlations between IL-34, PTPRZ1, syndecan-1 and myeloid cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.